These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
394 related items for PubMed ID: 15383733
1. Pitfalls in the imaging diagnosis of hepatocellular nodules in the cirrhotic and noncirrhotic liver. Yoshimitsu K, Irie H, Aibe H, Tajima T, Nishie A, Asayama Y, Matake K, Nakayamka T, Kakihara D, Honda H. Intervirology; 2004; 47(3-5):238-51. PubMed ID: 15383733 [Abstract] [Full Text] [Related]
2. Dysplastic nodules in cirrhotic liver: arterial phase enhancement at CT and MR imaging--a case report. Krinsky GA, Theise ND, Rofsky NM, Mizrachi H, Tepperman LW, Weinreb JC. Radiology; 1998 Nov; 209(2):461-4. PubMed ID: 9807574 [Abstract] [Full Text] [Related]
3. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging. Quaia E, Pizzolato R, De Paoli L, Angileri R, Ukmar M, Cova MA. J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278 [Abstract] [Full Text] [Related]
4. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Muhi A, Araki T. Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092 [Abstract] [Full Text] [Related]
5. How to differentiate liver lesions in cirrhosis. Bartolozzi C, Crocetti L, Della Pina MC. JBR-BTR; 2007 Jul; 90(6):475-81. PubMed ID: 18376759 [Abstract] [Full Text] [Related]
6. From the RSNA refresher courses: screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging: opportunities and pitfalls. Baron RL, Peterson MS. Radiographics; 2001 Oct; 21 Spec No():S117-32. PubMed ID: 11598252 [Abstract] [Full Text] [Related]